CME - CME Group Inc.
CME Group (NASDAQ: CME) reported record second-quarter revenue and near-record trading activity, while executives used much of the company's second-quarter 2026 earnings call to address investor questions about perpetual futures and outline a slate of new product launches. Chairman and CEO Terry Duffy said second-quarter average daily volume was 29.8 million contracts, the second-highest second quarter
CME Group has underperformed the S&P 500, declining nearly 12% over the past 11 months. CME delivered solid Q2 2026 results, with EPS of $2.99 and revenue of $1.71B, both of which beat analysts' expectations. Market Data revenue surged more than 20% compared to the same period a year ago.
CME Group is rated Buy, supported by record results and a resilient, defensible futures franchise. CME's moat is anchored in open interest and margin efficiencies, not just market share, insulating it from FMX's cash bond competition. Three underappreciated growth drivers: Treasury clearing, retail expansion, and crypto, are poised to fuel future compounding.
CME Group maintains strong core performance, posting record Q2 revenue and robust margins, yet the stock remains range-bound and fully valued. Q2 2026 highlights include $2.99 non-GAAP EPS, $1.71B revenue, 69.5% adjusted operating margin, and resilient trading volumes across key product lines. Capital return remains aggressive with $1.2B distributed via dividends and buybacks, backed by a strong balance sheet and disciplined expense management.
CME Group beat Wall Street's second-quarter profit estimates on Wednesday, fueled by strong hedging demand, sending the derivatives exchange's shares up 6.1%.
CME Group Inc. (CME) Q2 2026 Earnings Call Transcript
Seagate Technology shares continued to advance as demand for high-capacity storage tied to AI data-center buildouts supported further positive earnings revisions. On balance, the Fund's artificial intelligence positioning was a net positive contributor to relative performance during the quarter. We added the Humana position on the view that earnings are at a cyclical trough, with MA margins currently depressed, in some cases negative, as elevated medical cost trends have outpaced premium growth across the industry.
CME Group beats Q2 estimates as record market data revenues and resilient trading activity lift results, while expanding its product lineup.
Although the revenue and EPS for CME (CME) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CME Group NASDAQ: CME reported record second-quarter revenue and near-record trading activity, while executives used much of the company's second-quarter 2026 earnings call to address investor questions about perpetual futures and outline a slate of new product launches.
CME Group (CME) came out with quarterly earnings of $2.99 per share, beating the Zacks Consensus Estimate of $2.91 per share. This compares to earnings of $2.96 per share a year ago.
CHICAGO, July 22, 2026 /PRNewswire/ -- CME Group Inc. (NASDAQ: CME) today reported financial results for the second quarter of 2026. The company reported revenue of $1.7 billion and operating income of $1.1 billion for the second quarter of 2026.
US equities advanced during Q2, supported by another quarter of better-than-expected corporate earnings and continued enthusiasm for companies benefiting from artificial intelligence-related investment. Our bottom five contributors to return in Q2 were Accenture, CME Group, Salesforce, Boston Scientific and EOG Resources. Our top five contributors to return in Q2 were Texas Instruments, Lam Research, NXP Semiconductors, Elevance Health and Alphabet.
CHICAGO, July 21, 2026 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced plans to launch Sorghum basis futures. Trading is expected to start on August 24, 2026, pending regulatory review.
Get a deeper insight into the potential performance of CME (CME) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
CME Group's Q2 results are expected to reflect resilient revenue growth from market data and volatility-driven trading despite mixed contract volumes.
CME (CME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kalshi just launched a way to trade the future price of AI computing power, putting a CFTC-regulated startup on a collision course with the two biggest names in derivatives. The exchange that wins this land grab could own a market its founders say will eventually dwarf oil futures.
Prediction markets like Kalshi and Polymarket are betting on growth across new financial products. The industry's product menu already stretches from political elections and World Cup matches to weather events.
The U.S. Commodity Futures Trading Commission (CFTC) said on Thursday it would exercise its authority to stay the listing of a contract that would have allowed CME Group to initiate 24/7 trading on crude oil futures as soon as Friday.